Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Heidi Mocikova, Kristyna Kupcova, Jana Markova, Lubica Gaherova, Maria Maco, Iva Hamova, Adriana Velasova, Alice Sykorova, Pavla Stepankova, Alexandra Kredatusova, Vit Prochazka, Jan Koren, Petr Nehasil, Petra Zemankova, Tomas Kozak, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6193.

https://doi.org/10.1182/blood-2024-210890

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Blood (2024) 144 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2024-200323

Published: 2024

Journal Articles

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Andrea Hruskova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Alice Sykorova, Michal Masar, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2024-208416

Published: 2024

Journal Articles

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Veronika Hanackova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Eva Konirova, Tomas Prochazka, Kamila Polgarova, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1711.

https://doi.org/10.1182/blood-2024-204795

Published: 2024

Journal Articles

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Blood (2023) 142 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2023-181249

Published: 2023

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Kamila Polgarova, Andrea Janíková, David Belada, Vit Prochazka, Juraj Ďuraš, Heidi Móciková, Kateřina Steinerová, Vít Campr, Petra Blahovcová, David Zogala, Václav Ptáčník, Marek Trneny

Blood (2022) 140 (Supplement 1): 3831–3832.

https://doi.org/10.1182/blood-2022-163113

Published: 2022

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Aleš Obr, Pavel Klener, Jr., Andrea Janíková, Heidi Mocikova, David Belada, David Šálek, Alice Sýkorová, Andrea Jirkuvová, Tomáš Papajík, Marek Trněný

Blood (2021) 138 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2021-146589

Published: 2021

Journal Articles

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sykorova, David Belada, Marie Lukasova, Vit K Prochazka, Katarina Hradska, Juraj Ďuraš, Ondrej Havranek, Tomas Kozak

Blood (2021) 138 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2021-148363

Published: 2021

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Blood (2018) 132 (22): 2389–2400.

https://doi.org/10.1182/blood-2018-06-855502

Published: 2018

Includes: Supplemental data

Journal Articles

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Pavel Otahal, MD PhD, Andrea Janikova, MD PhD Assoc Prof, David Belada, MD PhD, Vit Prochazka, MD, Heidi Mocikova, MD PhD, Jan Pirnos, Juraj Ďuraš, Kateřina Kopečková, Vit Campr, MD PhD, Robert Pytlik, Petra Blahovcova, Mgr, Marek Trneny, MD CSc

Blood (2018) 132 (Supplement 1): 5413.

https://doi.org/10.1182/blood-2018-99-117110

Published: 2018

Journal Articles

Elderly Hodgkin Lymphoma - Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry

Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Vit Prochazka, MD PhD Assoc Prof, Marie Lukasova, MD, Pavla Stepankova, MD, David Belada, MD PhD, Katerina Klaskova, MA, Lubica Gaherova, MD, Karel Chroust, MA, PhD, Jana Markova, MD

Blood (2017) 130 (Supplement 1): 2792.

https://doi.org/10.1182/blood.V130.Suppl_1.2792.2792

Published: 2017

NARROW

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Elderly Hodgkin Lymphoma - Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only